News

Navigating compliance: outsourced regulatory services versus the DIY approach

In the dynamic landscape of medical device and in vitro diagnostic (IVD) manufacturing, balancing the critical elements of time, resources and regulatory compliance is crucial, reports Phyllis Meng, cofounder and CEO of Pure Global.

Published on:
June 5, 2024

This article was originally published in Manufacturing Chemist.

The recent enforcement of the EU’s Medical Device Regulation (MDR) and In vitro Diagnostic Device Regulation (IVDR), coupled with heightened global cybersecurity scrutiny, has added layers of complexity to an already intricate process.1

Consequently, what once might have been a straightforward journey through regulatory pathways — such as the US FDA 510(k) route‚ now demands a more nuanced approach.

Whether you’re a startup or an established multinational corporation, navigating through shifting regulatory landscapes is key to achieving success in this market. To address these challenges, companies must carefully consider their approach to regulatory compliance.

One critical decision revolves around the choice between outsourced regulatory services and the do-it-yourself (DIY) approach. Outsourcing regulatory tasks to specialised firms ensures access to experience and efficiency, allowing companies to focus on core business activities.

Conversely, opting for a DIY approach provides greater control … but requires significant time, resources and expertise to ensure compliance. Balancing these factors is essential for companies striving to maintain competitiveness in an increasingly regulated industry.

As a result, one question arises: is one approach better than the other?

Exploring regulatory challenges

Regulatory compliance goes beyond a mere checkbox; it forms the foundation of product safety, effectiveness and market acceptance.

Efficiently managing regulatory challenges involves understanding the intricacies of various regulations, staying updated about revisions and amendments, and implementing robust systems and processes to ensure compliance.2

The regulatory landscape is constantly changing, presenting both obstacles and opportunities for manufacturers. Whether it’s navigating the complexities of MDR and IVDR or addressing emerging cybersecurity concerns, staying ahead requires proactive involvement and strategic planning.

After all, regulatory challenges don’t just encompass technical criteria, there’s also documentation, quality management and post-market surveillance to consider.

In the face of evolving regulatory demands, companies must assess their internal capacity to tackle these challenges effectively.

Although some organisations may have the expertise and resources to manage regulatory affairs in-house, others may benefit from outsourcing these functions to specialised service providers.

Ultimately, the decision between a DIY approach and outsourced regulatory services depends on factors such as organisational capabilities, scalability and risk tolerance.

The DIY approach

Opting for the DIY approach allows companies to tailor compliance strategies to their specific products, processes and needs. This autonomy enables businesses to retain control of the regulatory process and customise strategies to meet their individual needs.

However, this approach is not without its challenges. It demands substantial monetary investments in talent acquisition, infrastructure development and ongoing training to keep pace with the constantly evolving regulatory landscape.  

Then, it’s crucial to consider that navigating legislative complexities without specialised expertise can lead to compliance gaps, delays in product approvals and increased regulatory scrutiny.

For instance, although the internal staff may have the capability to overcome certain hurdles, the time required to get up to speed, learn how to navigate a constantly changing environment and establish appropriate processes can set them back significantly.

This is why it’s essential to evaluate your internal capacity to manage and understand new and ongoing regulatory demands.

For example, do you have a full understanding of the clinical data that you’ll need to collect for your EU Post-Market Clinical Follow-Up under MDR? Do you have the expertise or personnel to design, establish, run and analyse results from any required clinical studies?

Another critical area is cybersecurity, especially for software-based medical devices. Do your regulatory and engineering teams have the knowledge to assess and mitigate current and ongoing risks?

Although the DIY approach offers significant control and customisation benefits, it also requires a thorough evaluation of your internal capabilities and resources. Ultimately, investing in the necessary talent, infrastructure and training is essential to ensure compliance and mitigate risks effectively.

Outsourced regulatory services

By collaborating with experienced consultants or service providers, businesses can optimise the regulatory procedure, mitigate risks and expedite time-to-market. For instance, the expertise and experience of these outside specialists guarantee adherence to intricate and changing regulatory standards.

This expertise is particularly valuable when navigating new regulations or entering new markets, wherein the intricacies of local regulatory landscapes can be challenging to understand.

Scalability is another significant benefit of outsourcing regulatory services. Companies can adjust the level of support they receive based on their current needs, whether it’s ramping up for a new product launch or scaling down during quieter periods.

Without making long-term commitments to hire more internal staff, this flexibility enables businesses to respond quickly to changes in regulatory requirements and helps to manage costs more effectively.

As a result, outsourcing also allows businesses to focus on core competencies and business growth while leveraging external resources for regulatory support.

Then, it’s also worth considering that outsourcing can provide access to a global network of regulatory professionals, offering diverse perspectives and insights that can improve strategic decision making.

Overall, outsourcing regulatory services offers companies a strategic advantage by providing access to specialised expertise, enhancing scalability and achieving cost efficiencies

Conclusion: streamlining compliance

The choice between outsourced regulatory services and the DIY approach is a strategic decision that requires the careful consideration of organisational capabilities, regulatory complexities and long-term objectives.

Companies must evaluate their internal resources, expertise and the specific demands of the regulatory environment they operate in.

However, a key consideration in this decision is the time and effort required to bring a new product to launch or to maintain an existing product’s market presence. Delays in regulatory approval can lead to increased costs and missed market opportunities.

Additionally, the longer it takes to achieve compliance, the greater the risk that allocated resources will be depleted. Ultimately, companies must weigh the benefits of specialised expertise and efficiency against the need for control and customisation.

Regardless of the chosen path, efficiently managing regulatory challenges is essential to sustain competitiveness and ensure patient safety in the dynamic landscape of medical device and IVD manufacturing.

References

  1. https://english.igj.nl/medical-technology/new-european-regulations-mdr-and-ivdr.
  2. https://medtechintelligence.com/ate/what-is-regulatory-excellence-in-the-medical-technology-world/.

Subscribe to newsletter
Subscribe to receive the latest blog posts to your inbox every week.
By subscribing, you agree to our Terms and Conditions.
Thank you for subscribing!
Oops! Something went wrong while submitting the form.
Read more

Latest News

Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.

Pure Global is proud to announce its inclusion in the China Business Service Providers (BSP) directory on the International Trade Administration website.

Regulatory Update
November 20, 2024

This week in medical device regulatory news, Thailand has introduced new refer and transfer guidelines, Europe released an updated Q&A on IVDR and MDR vigilance terms, and Romania has new rules for Economic Operators.

Regulatory Update
November 13, 2024

This week, we bring you medical device regulatory update coverage from around the world, including new registration Q&A resources in Taiwan and Japan, UK relaunches ILAP pathway, Mexico will apply a new acquisition model, and more.

Key deadlines and questions in vitro diagnostic manufacturers need to consider to comply with IVDR Amendment EU 2024/1860.

Contact us
Request information

Let's Talk,
Anywhere You Are.

Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.

Our closest representative will get back to you within 24 hours.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Latest Blog Content

Explore our collection of articles, success stories, and regulatory updates, designed to help you take your product global.

Risk increases compliance chalenges under IVDR
Blog Article
What are the challenges under IVDR?

IVD manufacturers cite the new classification system, detailed definitions for intended purposes, and the need for verification of clinical evidence as key challenges under the IVDR.

Blog Article
EU Parliament Revises MDR and IVDR

On October 23, the European Parliament adopted a resolution revising specific elements of the Medical Devices Regulation (MDR) and the In Vitro Diagnostic Devices Regulation (IVDR). This resolution intends to address ongoing challenges in implementing the regulations by 2025 and to improve patient access to important medical products.

Blog Article
Language Challenges in MedTech Going Global and Our Solution

Multilingual documentation presents ongoing compliance and logistical hurdles for MedTech manufacturers. Transla.Ai is an industry-specific translation tool that can accelerate and streamline the translation process.

Medical device supply chain
Blog Article
Managing your medical device supply chain

The connection between supplier controls and business risks is becoming increasingly evident. In this article, we discuss perspectives on how to maintain a compliant medical device supply chain.